Karin Vanderkerken

12.2k total citations · 1 hit paper
227 papers, 7.9k citations indexed

About

Karin Vanderkerken is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Karin Vanderkerken has authored 227 papers receiving a total of 7.9k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Hematology, 128 papers in Molecular Biology and 91 papers in Oncology. Recurrent topics in Karin Vanderkerken's work include Multiple Myeloma Research and Treatments (145 papers), Protein Degradation and Inhibitors (36 papers) and Histone Deacetylase Inhibitors Research (28 papers). Karin Vanderkerken is often cited by papers focused on Multiple Myeloma Research and Treatments (145 papers), Protein Degradation and Inhibitors (36 papers) and Histone Deacetylase Inhibitors Research (28 papers). Karin Vanderkerken collaborates with scholars based in Belgium, United Kingdom and United States. Karin Vanderkerken's co-authors include Eline Menu, Ivan Van Riet, Els Van Valckenborgh, Ben Van Camp, Elke De Bruyne, Kewal Asosingh, Hendrik De Raeve, Peter I. Croucher, Kim De Veirman and Ken Maes and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Karin Vanderkerken

221 papers receiving 7.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells

2014 366 citations Miguel Lemaire, Elke De Bruyne et al. Blood profile →

Peers

Countries citing papers authored by Karin Vanderkerken

Since Specialization

Citations

This map shows the geographic impact of Karin Vanderkerken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karin Vanderkerken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karin Vanderkerken more than expected).

Fields of papers citing papers by Karin Vanderkerken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karin Vanderkerken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karin Vanderkerken. The network helps show where Karin Vanderkerken may publish in the future.

Co-authorship network of co-authors of Karin Vanderkerken

This figure shows the co-authorship network connecting the top 25 collaborators of Karin Vanderkerken. A scholar is included among the top collaborators of Karin Vanderkerken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karin Vanderkerken. Karin Vanderkerken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Immunopeptidomics identified antigens for mRNA-lipid nanoparticle vaccines with alpha-galactosylceramide in multiple myeloma therapy 2025 ·Journal for ImmunoTherapy of Cancer ·(unknown), Fabien Théry, (unknown), (unknown), (unknown), (unknown), (unknown), Kim De Veirman, Karin Vanderkerken, Elke De Bruyne, Lorenzo Franceschini, Francis Impens, Rein Verbeke, Ine Lentacker, Eline Menu, Karine Breckpot	0
2	AXL as immune regulator and therapeutic target in Acute Myeloid Leukemia: from current progress to novel strategies 2024 ·Experimental Hematology and Oncology ·(unknown), Nathan De Beule, Ann De Becker, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Karine Breckpot, Nick Devoogdt, Kim De Veirman	4
3	Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis 2023 ·The Journal of Pathology ·(unknown), (unknown), Gamze Ates, Sylvia Faict, Philip Vlummens, (unknown), Rong Fan, Anke Maes, Ann Massie, Kim De Veirman, Elke De Bruyne, Karin Vanderkerken, Eline Menu	12
4	Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions 2022 ·International Journal of Molecular Sciences ·(unknown), (unknown), Sofie Deschoemaeker, Geert Raes, Anke Maes, Elke De Bruyne, Eline Menu, Karin Vanderkerken, Damya Laoui, Kim De Veirman	30
5	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma 2022 ·Frontiers in Immunology ·(unknown), Robin Maximilian Awad, Veronica Basso, Noëlia Casares, Kirsten De Ridder, Yannick De Vlaeminck, (unknown), Cleo Goyvaerts, Quentin Lecocq, Edurne San José‐Eneriz, Stefaan Verhulst, Ken Maes, Karin Vanderkerken, Xabier Agirre, Felipe Prósper, Juan José Lasarte, Anna Mondino, Karine Breckpot	7
6	Pyrroline-5-Carboxylate Reductase 1: a novel target for sensitizing multiple myeloma cells to bortezomib by inhibition of PRAS40-mediated protein synthesis 2022 ·Journal of Experimental & Clinical Cancer Research ·(unknown), (unknown), Philip Vlummens, (unknown), Anke Maes, Dirk Hose, Elke De Bruyne, Bart Ghesquière, Karin Vanderkerken, Kim De Veirman, Eline Menu	26
7	A distinct metabolic response characterizes sensitivity to EZH2 inhibition in multiple myeloma 2021 ·Cell Death and Disease ·(unknown), (unknown), Jakob Haglöf, Elke De Bruyne, Eline Menu, (unknown), Anqi Ma, Jian Jin, Fredrik Öberg, Karin Vanderkerken, Antonia Kalushkova, Helena Jernberg‐Wiklund	16
8	Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion 2017 ·Cancer Immunology Research ·Kim De Veirman, Nathan De Beule, Ken Maes, Eline Menu, Elke De Bruyne, Hendrik De Raeve, Karel Fostier, Jérôme Moreaux, Alboukadel Kassambara, Dirk Hose, Roy Heusschen, Helena Eriksson, Karin Vanderkerken, Els Van Valckenborgh	44
9	Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression 2017 ·Cancer Research ·Eva De Smedt, Ken Maes, Stefaan Verhulst, Hui Lui, Alboukadel Kassambara, Anke Maes, Nicolas Robert, Carlo Heirman, Andrew Cakana, Dirk Hose, Karine Breckpot, Leo A. van Grunsven, Kim De Veirman, Eline Menu, Karin Vanderkerken, Jérôme Moreaux, Elke De Bruyne	30
10	A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement 2016 ·Clinical Cancer Research ·Leo Rasche, Emmanuelle Ménoret, Valentina Dubljevic, Eline Menu, Karin Vanderkerken, Constantin Lapa, Torsten Steinbrunn, Manik Chatterjee, Stefan Knop, (unknown), Deanne L.V. Greenwood, Frank Hensel, Andreas Rosenwald, Hermann Einsele, Stephanie Brändlein	47
11	Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro 2013 ·Molecular Cancer Therapeutics ·Jinsong Hu, Els Van Valckenborgh, Dehui Xu, Eline Menu, Hendrik De Raeve, (unknown), Song Xu, Ben Van Camp, Damian Handisides, Charles P. Hart, Karin Vanderkerken	49
12	Sorafenib Has Potent Antitumor Activity against Multiple Myeloma In Vitro , Ex Vivo , and In Vivo in the 5T33MM Mouse Model 2012 ·Cancer Research ·Pedram Kharaziha, Hendrik De Raeve, (unknown), Qiao Li, Astrid Gruber, Per Johnsson, Georgia Kokaraki, (unknown), Edward Laane, Anders Österborg, Boris Zhivotovsky, Helena Jernberg‐Wiklund, Dan Grandér, Fredrik Celsing, Magnus Björkholm, Karin Vanderkerken, Theocharis Panaretakis	42
13	The HDAC Inhibitor LBH589 Enhances the Antimyeloma Effects of the IGF-1RTK Inhibitor Picropodophyllin 2012 ·Clinical Cancer Research ·Miguel Lemaire, (unknown), Prasoon Agarwal, Eline Menu, Els Van Valckenborgh, Elke De Bruyne, Anders Österborg, Peter Atadja, Olle Larsson, Magnus Axelson, Ben Van Camp, Helena Jernberg‐Wiklund, Karin Vanderkerken	13
14	The role of the bone marrow microenvironment in multiple myeloma. 2005 ·PubMed ·(unknown), Karin Vanderkerken	42
15	Of mice and men, disease models of multiple myeloma. 2004 ·Open Repository and Bibliography (University of Liège) ·Jo Caers, Kewal Asosingh, Ben Van Camp, Ivan Van Riet, Karin Vanderkerken	1
16	Multifunctional role of matrix metalloproteinases in multiple myeloma: study in the 5T2mm mouse model. 2004 ·VUBIR (Vrije Universiteit Brussel) ·Els Van Valckenborgh, Peter I. Croucher, Hendrik De Raeve, Evy De Leenheer, Silvia Blacher, Laetitia Devy, Kewal Asosingh, Ivan Van Riet, Benjamin Van Camp, Karin Vanderkerken	1
17	Angiogenesis and the role of bone marrow endothelial cells in haematological malignancies. 2004 ·PubMed ·Hendrik De Raeve, Eric Van Marck, B Van Camp, Karin Vanderkerken	32
18	Bone marrow endothelial cells express the osteoclastogenic factor RANKL and its decoy receptor OPG: Evidence for a role in the development of myeloma bone disease. 2002 ·Blood ·Evy De Leenheer, Karin Vanderkerken, Marleen Bâkkus, Benjamin Van Camp, C M Shipman, Peter I. Croucher	2
19	Osteoprotegerin (OPG) inhibits the development of osteolytic bone disease in the 5T2MM model of multiple myeloma. 2000 ·Blood ·Peter I. Croucher, C M Shipman, Mark Perry, J M Lippitt, Kewal Asosingh, (unknown), B Van Camp, R.G.G. Russell, Colin R. Dunstan, Karin Vanderkerken	1
20	Bone marrow microenvironmental-induced upregulation of MMP-9 activity in murine multiple myeloma cells 2000 ·Clinical & Experimental Metastasis ·Karin Vanderkerken, Els Van Valckenborgh, Marleen Bâkkus, Carine Munaut, Agnès Noël, Kewal Asosingh, Ivan Van Riet, (unknown), Yves St‐Pierre, Benjamin Van Camp	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact